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NEOPLASIA
Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize
acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis
independent of other antiapoptotic proteins
Marina Konopleva,Ana M. Tari, Zeev Estrov, David Harris, Zhong Xie, Shourong Zhao, Gabriel Lo ´pez-Berestein, and MichaelAndreeff
The antiapoptotic proteins, Bcl-2 and
Bcl-XL, are expressed in most cases of
acute myeloid leukemia (AML) and may
contribute to drug resistance in AML. We
tested the hypothesis that down-regula-
tion of Bcl-2 alone by antisense oligode-
oxynucleotides (Bcl-2-AS) induces apop-
tosis, even in the presence of other
antiapoptotic genes. We tested Bcl-2-AS
in myeloid leukemic HL-60 cells, in Bcl-2
and Bcl-XL overexpressing HL-60-DOX
cells, and in primaryAMLsamples. Down-
regulation of Bcl-2 by Bcl-2-AS reduced
the viability of HL-60 cells and, less
effectively, HL-60-DOX cells and in-
creased ara-C cytotoxicity in both cell
lines. Incubation of primary AML blasts
with Bcl-2-AS decreased Bcl-2 expres-
sion in CD341 blast cells after induction
of apoptosis and enhancement of ara-C
cytotoxicity in 11 of 19 primary AML
samples. In 8 samples in which Bcl-2-AS
did not induce apoptosis, baseline Bcl-2
levels were found to be strikingly high.
The expression of other antiapoptotic
proteins (Bcl-XL, Bag-1,A1, and Mcl-1) did
not prevent Bcl-2-AS–induced apoptosis.
Bcl-2-AS also inhibited colony formation
of AML progenitor cells. Low concentra-
tions of Bcl-2-AS induced signiﬁcant
increases in S-phase cells (P 5 .04). Re-
sults establish Bcl-2 as a critical target
for AS strategies in AML in which the
baseline levels predict response to Bcl-2-
AS. Bcl-2 exerts both antiapoptotic and
antiproliferative functions in AML. Be-
cause early normal hematopoietic stem
cells do not express Bcl-2, Bcl-2-AS
therapy should be highly selective for
AML cells. (Blood. 2000;95:3929-3938)
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Introduction
Physiologic cell death (apoptosis) is controlled by an intrinsic
genetic program that is remarkably conserved in evolution. All
currently available cytotoxic drugs induce tumor death by trigger-
ing apoptosis. However, many tumors have defects in the regula-
tion of genes that control apoptosis. This may contribute to their
growth and also render them resistant to chemotherapeutic agents.
Members of the Bcl-2 family regulate a distal step in the cell death
pathway. Although its mechanism of action is still unclear, Bcl-2
appears to function as a suppressor of cell death that can be
triggered by a variety of signals. In gene transfection experiments,
overexpression of Bcl-2 and its homolog Bcl-XL can render
neoplastic cells resistant to the induction of apoptosis by a variety
of chemotherapeutic drugs.1-5
Likewise, down-regulation of the Bcl-2 protein has been shown
to reverse chemoresistance in several experimental systems.6-9 In
acute myeloid leukemia (AML), high Bcl-2 levels are associated
with resistance to chemotherapy, decreased rates of complete
remission, and shortened survival.10-14
Recently, it was demonstrated that Bcl-2 not only inhibits
apoptosis but also restrains cell cycle entry15-17 and that these 2
functions can be genetically dissociated.18 This antiproliferative
effect could provide additional cytoprotection because proliferating
cells are more vulnerable to apoptotic stimuli. Therefore, agents
that can overcome the inhibitory effects of Bcl-2 on cell cycle entry
could be a useful adjunct to currently available chemothera-
peutic drugs.
Inhibiting the function of Bcl-2 might have a more pronounced
effect on neoplastic cells than on normal cells, that is, the loss of
cell cycle control mechanisms drives cells into the cell cycle,
despite drug-induced damage.19 Inactivation of the G1 cell cycle
checkpoint occurs when p53 is inactivated, either by mutation or
deletion.20 Cells, then, do not arrest and repair DNA damage but
proceed through the cell cycle and undergo programmed cell death.
It is known that the most primitive hematopoietic precursors
express Bcl-XL but not Bcl-2.21,22 Bcl-2 is universally expressed in
AML progenitors cells, and a subset of patients with AML have
higher levels of expression than normal CD341 cells.10,14 Results
from our group and others indicate that retinoids down-regulate the
expression of Bcl-2, and can enhance the effect of chemotherapy in
vitro.22,23 Recent data suggest the ability of all-trans retinoic acid to
inactivateBcl-2byphosphorylation.24Antisenseoligodeoxynucleo-
tides targeted against Bcl-2 have been used to induce apoptosis of
malignantcellsortosensitizethemtoconventionalchemotherapeu-
tic drugs,6-8 and the ﬁrst clinical study of Bcl-2 antisense therapy in
patients with recurrent non-Hodgkin’s lymphoma was recently
reported.25Otherstudiessuggestthatliposomaldeliveryofoligode-
oxynucleotides may circumvent the poor cellular uptake and
delivery of antisense oligodeoxynucleotides alone.26 We have
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esters enhances nuclease resistance and increases incorporation
efficiency into liposomes.27 Experimental animal models indicate a
lack of signiﬁcant adverse effects such as autoimmunity and organ
toxicity. Liposomal oligodeoxynucleotides are mainly distributed
to the liver, spleen, and bone marrow, which are the major organs of
leukemic manifestation.28 Thus, liposomal delivery of anti-Bcl-2
oligodeoxynucleotides(Bcl-2-AS)incombinationwithchemothera-
peutic agents and biologic response modiﬁers may potentially be
used as novel treatment modalities for hematologic malignancies.
In this study, we used liposomally delivered Bcl-2-AS to induce
down-regulation of the Bcl-2 protein in AML cells. Similar
approaches in different tumor models have resulted in decreased
cell survival,29,30 the induction of apoptotic cell death,31 and
increased drug sensitivity in vitro and in vivo.6,32 Because other
antiapoptotic proteins are expressed in AML,22,33 we wished to
investigate whether Bcl-2 was critical for AML survival and if
apoptosis could be induced, in particular, despite high levels of
antiapoptotic Bcl-XL, which is expressed in mostAML.22,34,35 Also,
we wished to investigate what levels of cellular Bcl-2 are critical
for the survival and chemoresistance of primaryAMLcells.
Materials and methods
Cell lines
We used 2 AML cell lines, HL-60 and the 60-doxorubicin-resistant
subline/HL-60-DOX.
36 Both express Bcl-2, but HL-60-DOX cells were
previously found by us to express signiﬁcantly higher amounts of both
antiapoptotic proteins, Bcl-2 and Bcl-XL.37 Cell lines were cultured in
RPMI medium supplemented with 10% heat-inactivated fetal calf serum
(FCS) at 37°C under 5% CO2 in a humidiﬁed incubator.
Subjects
Samples of bone marrow or peripheral blood for in vitro studies from newly
diagnosed or recurrentAML with a high (more than 40%) blast count were
obtained under informed consent according to institutional guidelines.
Mononuclear cells were separated by Ficoll-Hypaque (Sigma Chemical, St
Louis, MO) density-gradient centrifugation.
Preparation of liposomal oligodeoxynucleotides
P-ethoxy oligodeoxynucleotides (ODN) (Oligos Etc, Willsonville, OR)
were chosen because this modiﬁcation makes ODN nuclease resistant and
canbeefficientlyincorporatedintoliposomes.Liposomaloligodeoxynucleo-
tides were prepared as previously described.38 Brieﬂy, ODN dissolved in
DMSO were added to phospholipids (Avanti Polar Lipids,Alabaster,AL) in
the presence of excess tert-butanol. The mixture was frozen in a dry
ice/acetone bath, lyophilized overnight, and ﬁnally hydrated with 0.9%
normal saline at a ﬁnal oligodeoxynucleotide concentration of 0.1 mmol/L.
For Bcl-2-AS, we used a sequence, which is complimentary to the Bcl-2
translation initiation site (58-CAGCGTGCGCCATCCTTCCC-38).39
Scrambled sequence (nonsense, NS) oligodeoxynucleotides (58-TCGC-
CACTCGATCCTGCCCG-38) and empty liposomes were used as controls.
Suspension culture of leukemic cells
HL-60 and HL-60-DOX cells were cultured at 2.5 3 104 cells/mL, and
AML mononuclear cells were seeded at 5 3 105 cells/mL. Cells were
cultured in complete media (RPMI supplemented with 10% fetal calf serum
[FCS]) in the presence or absence of liposomal Bcl-2-AS or NS at an
appropriate concentration (see below). Empty liposomes were also included
as controls. Granulocyte colony-stimulating factor (G-CSF) (200 U/mL)
was added to cultures of fresh AML cells. In previous studies, we
demonstrated that G-CSF and granulocyte-macrophage colony-stimulating
factor (GM-CSF) support proliferation and block spontaneous apoptosis of
AMLblasts without affecting average Bcl-2 expression levels.40 For protein
and apoptosis studies, a ﬁnal concentration of 8 µmol/L ODN was used.
These studies were repeated 3 times.
For cytotoxicity studies, 1 µmol/Lara-C was added to the cultures.After
72 hours, viable cells were counted with the trypan blue-dye exclusion
method using a hematocytometer, and the viability of the leukemic cells
was determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulphenyl)-2H-tetrazolium (MTS) assay as described below.
Quantitation of viability (MTS assay)
To determine cell viability, leukemic cells were seeded at a density of
2.5 3 103 cells per well in 96-well plates (Costar, Cambridge, MA). Six
hours later, liposomal Bcl-2-AS, NS, or empty liposomes were added to the
cells at a ﬁnal concentration of 2 to 20 µmol/L.After 5 days of culture, cell
viability was measured using the Cell Titer 96 AQ Non-Radioactive Cell
Proliferation Assay (Promega, Madison, WI). This assay is based on the
ability of viable cells only to reduce MTS to formazan, which can be
measured with a spectrophotometer at an absorbance of 490 nm. MTS
solution (2 mL) was mixed with 100 µL of phenazine methosulfate (PMS)
immediately before being added to the cells in the culture plate. The
MTS/PMS solution (20 µL) was than added to each well to maintain a
ratio of 20 µL MTS/PMS to 100 µL medium. After 1 hour, the reduction
product was measured at an absorbance of 490 nm and compared with a
standard curve.
Quantitation of Bcl-2 protein by ﬂow cytometry
The cellular content of Bcl-2 was measured in conjunction with the CD34
antigen in AML blast cells. Brieﬂy, after staining with phycoerythrin
(PE)-conjugated anti-CD34 monoclonal antibody (HPCA-2; Becton Dick-
inson, San Jose, CA), cells were washed twice and ﬁxed in 1% formalde-
hyde (Sigma) for 15 minutes on ice, followed by permeabilization with
0.1% Triton X in phosphate-buffered albumin (1% albumin, 0.1% NaN3)
for 10 minutes at 4°C. Cells were then washed in cold phosphate-buffered
saline (PBS) before being added to 10 µL of ﬂuorescein isothiocyanate
(FITC)-conjugatedanti-Bcl-2orisotypeIgG1monoclonalantibody(DAKO,
Carpinteria, CA). Dead cells were eliminated by gating, based on their
scatter (high side scatter and/or low forward scatter) characteristics, and
Bcl-2 expression was measured selectively on live cells. The intensity of
Bcl-2–associated ﬂuorescence was measured on a logarithmic scale. Bcl-2
was quantitated using Quantum Simply Cellular microbeads with QuickCal
Software (Flow Cytometry Standard, Triangle Park, NC), as previously
described,41,42 and expressed as the antibody-binding capacity (ABC),
which is an estimate of the number of antibody molecules bound per cell.A
FACScan ﬂow cytometer (Becton Dickinson) equipped with an argon laser
(488 nm) was used to measure ﬂuorescence. For each sample, 10 000 cells
were analyzed; cells were live-gated for CD34 positivity. Data were
analyzed using Lysys software (Becton Dickinson).
Detection of apoptotic cells and cell kinetics studies
Cell cycle kinetics were determined by staining cells with acridine orange
for cellular DNA and RNA content, followed by ﬂow cytometric analysis.
This method is able to discriminate cells in G0,G 1, S, and G2M phases and
determines the mean RNA content per cell during each phase of the cell
cycle.43 A minimum of 30 000 cells were analyzed and the percentage of
cells in the S-phase was determined using ModFit software (Verity
Software House, Inc, Topsham, ME).
Detection of apoptotic cells based on DNA fragmentation
Aliquots (80 µL) of cells were mixed with 100 µL of solution containing
0.1% (vol/vol) Triton X-100, 0.05 mol/L HCl, 0.15 mol/L NaCl, and 8
µg/mL acridine orange (Polysciences, Warrington, PA). The cell ﬂuores-
cence was measured within 5 minutes of staining, using the logarithmic
scale of the FACScan ﬂow cytometer with a 488-nm excitation of a 15-mW
argon laser and ﬁlter settings for green (530 nm) (DNA) and red (585 nm)
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analysis. The percentage of cells in the ‘‘sub G1 region’’ deﬁned the
proportion of apoptotic cells in the tested populations. Cell debris was
deﬁned as events in the lowest 10% range of ﬂuorescence and eliminated
from analysis.
Acute myeloid leukemia blast colony assay
A previously described method was used to assay AML blast colony
formation.44,45 Bone marrow mononuclear cells containing more than 80%
blasts from the bone marrow of patients with AML were incubated for 24
hours in Iscove’s modiﬁed Dulbecco medium (IMDM) supplemented with
10% FCS and 50 ng/mL recombinant human GM-CSF (Immunex Inc,
Seattle, WA). Bcl-2-AS was added at the initiation of cultures at concentra-
tions of 4, 6, 8, and 12 µmol/L. Untreated cells and cells that were incubated
for 24 hours in the presence of 12 µmol/L NS and empty liposomes were
used as controls. After extensive washing, 1 3 105 AML cells were plated
in 0.8% methylcellulose in IMDM with 10% FCS and 50 ng/mL GM-CSF.
Duplicate cultures were incubated in 35-mm petri dishes for 7 days at 37°C
in a humidiﬁed atmosphere of 5% CO2 in air. AML blast colonies were
microscopically evaluated on day 7.Ablast colony was deﬁned as a cluster
of 40 or more cells. Individual colonies were plucked, smeared on glass
slides, and stained to conﬁrm leukemic cellular composition.As previously
described, theAMLblast colonies grown in this assay contained only blasts
and no normal progenitors.46
In 4 experiments, 2 3 105 CD341 cells isolated from normal bone
marrow (n 5 2) or G-CSF–stimulated peripheral blood (n 5 2) were plated
in methylcellulose after 24 hours of preincubation with Bcl-2-AS (4, 6, 8,
and 12 µmol/L) and 6 or 12 µmol/Lof NS and empty liposomes as described
above. Colony-forming unit–granulocyte macrophage (CFU-GM) and
colony-forming unit–eosinophil (CFU-E) were microscopically evaluated
on day 14 of culture.
Western blot analysis
Cells were lysed in protein lysis buffer. An equal amount of protein lysate
was placed on 8% SDS-PAGE for 2 hours at 100 V, followed by transfer of
the protein to a Nytran membrane (S&S, Heween, NH). Immunoblotting
was performed at room temperature for 2 hours with 5% milk before
incubation with the ﬁrst antibody in 1:1000 dilution for another 2 hours,
followed by 3 washings in phosphate-buffered saline (PBS). The procedure
was repeated for the secondary antibody. Blots were then soaked in ECL
buffer for 1 minute and exposed to ECL ﬁlms. Polyclonal rabbit antibodies
to Bcl-2, Bcl-XL, Bax, Bak, A1, Mcl-1,47-49 and a murine monoclonal
antibody to Bag-150 were used at 1:1000 dilution (kindly provided by Dr
J.C. Reed).
Statistical analysis
The statistical analysis was performed using the 2-tailed Student t test and
the Spearman rank correlation coefficient. Statistical signiﬁcance was
considered when P , .05. Unless otherwise indicated, average values were
expressed as mean 6 SEM.The chi-square test was used to compare effects
of Bcl-2-AS onAMLcells in vitro with several clinical features ofAML.
Results
Basal levels of Bcl-2 and Bcl-XL expression in leukemic
cell lines
The level of protein expression was examined in the HL-60
myeloid cell line and its drug-resistant counterpart, HL-60-DOX,
by quantitative ﬂow cytometry and Western blot analysis. As
shown in Figure 1A, HL-60-DOX cells express signiﬁcantly higher
levels of Bcl-2 than the parental HL-60 cells. Using a series of
calibrated FITC microbeads (see ‘‘Materials and methods’’), the
antibody-binding capacity per cell was calculated. HL-60 cells had
49 3 103 ABC per cell and HL-60-DOX had 86 3 103 ABC per
cell. By Western blot analysis, HL-DOX cells overexpressed both
Bcl-2 and Bcl-XL(Figure 1B).
Cytotoxic effects of Bcl-2-AS on HL-60 and HL-60-DOX
cell lines
The effect of Bcl-2-AS on the growth of leukemic cell lines was
tested using the MTS viability assay. Leukemic cells were incu-
bated with increasing concentrations of Bcl-2-AS or NS for 5 days
(Figure 2). The viability of HL-60 cells was effectively reduced by
Bcl-2-AS in a dose-dependent fashion (IC50 5 4 µmol/L). NS
exhibited only a modest effect with all concentrations used.
HL-60-DOX–resistant cells with a higher Bcl-2 and Bcl-XL content
required a higher concentration of Bcl-2-AS to achieve equivalent
toxicity (IC50 5 10 µmol/L), but were not protected by Bcl-XL.
Empty liposomes did not inhibit cell growth under similar condi-
tions, and NS only affected cell viability of HL-60-DOX cells when
used in concentrations greater than or equal to 16 µmol/L.
Interestingly, antisense oligonucleotides targeting the Bcl-XL trans-
lation initiation site were much less effective in killing HL-60 cells,
Figure 1. Bcl-2 expression in HL-60 and HL-60-DOX cells. (A) Flow cytometry
shows that HL-60-DOX cells have a signiﬁcantly higher Bcl-2 expression than HL-60
cells (P 5 .02). (B) HL-60-DOX and HL-60 cell lysates were Western blotted and
probed with Bcl-2 and Bcl-XL polyclonal antibodies. Loading of lanes was controlled
with actin, demonstrating that equivalent amounts of protein were blotted (results not
shown). Antimouse peroxidase and enhanced chemiluminiscence were used to
detect immunoreactive bands.
Figure 2. Effect of Bcl-2-AS on the viability of HL-60 and HL-60-DOX cells as
determined by MTS assay. The viability of HL-60 cells and HL-60-DOX–resistant
cells was effectively reduced by Bcl-2-AS in a dose-dependent fashion (IC50 5 4 and
10 µmol/L, respectively). NS and empty liposomes (EL) did not effect the cell viability.
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observations).
Bcl-2-AS induces apoptosis of leukemic cells. To investigate
the mechanism of dose-dependent inhibition of cell growth,
apoptotic cells were identiﬁed by ﬂow cytometry based on
differential staining with acridine orange (‘‘sub G1 region’’). HL-60
and HL-60-DOX cells were treated with 8 µmol/L Bcl-2-AS or NS
for 5 days. After permeabilization, cells were stained with acridine
orange and analyzed by ﬂow cytometry in 3 independent experi-
ments. The number of apoptotic HL-60 and HL-60-DOX cells
increased to 24.3% 6 5.1% and 25.3% 6 3.2%, respectively, after
treatment with Bcl-2-AS, compared with treatment with NS
(HL-60, 12.6% 6 4.8%; HL-DOX, 3.9 6 0.9, P 5 .01) and con-
trol cultures (HL-60, 5.8% 6 1.7%; HL-DOX, 2.3% 6 0.6%,
P 5 .005).
Bcl-2-AS reduces Bcl-2 protein levels in leukemic cells. To
examinethepostulatedsequence-speciﬁcdown-regulationoftarget
protein, we used Western blot analysis and ﬂow cytometry to
determine Bcl-2 protein levels after treatment with Bcl-2-AS in
leukemic cell lines. Western blot analysis of HL-60 cells after 5
days of treatment with 8 µmol/L Bcl-2-AS (Figure 3A) demon-
strated that the Bax protein was equally expressed in treated and
untreated cells, whereas expression of the Bcl-2 protein decreased
in cells treated with Bcl-2-AS but not in those treated with NS. By
ﬂow cytometry, Bcl-2 levels in HL-60 cells decreased slightly on
day 3 of incubation with 8 µmol/L Bcl-2-AS and decreased further
on day 5 (Figure 4A). Bcl-2 levels were quantitated using
microbeads with QuickCal Software and were expressed as anti-
body-binding capacity (ABC). In HL-60 cells, Bcl-2 expression
decreased from 49 3 103 o nd a y0t o3 03 103ABC per cell on day
3, and to 20 3 103 ABC per cell on day 5. In HL-60-DOX cells
treated with Bcl-2-AS, Bcl-2 decreased from 85.7 3 103 on day 0
to 43.4 3 103 ABC per cell on day 5 (Figure 4B). In cells treated
with NS, only an insigniﬁcant decrease was observed on day 5
(HL-60, 46 3 103 ABC per cell; HL-60-DOX, 73 3 103 ABC per
cell). Importantly, Bcl-2-AS decreased viability and down-
regulated Bcl-2 levels in Bcl-XL–-overexpressing HL-DOX cells.
Interestingly, an increase in Bcl-XL expression was observed
(Figure 3B).
Bcl-2-AS enhances ara-C induced cytotoxicity. We then
evaluated the sensitivity of HL-60 and HL-60-DOX cells to the
combination of Bcl-2-AS with ara-C. HL-60 cells were more
sensitive to 1 µmol/L ara-C (38.9% 6 4.2 viable cells, MTS assay)
than HL-60-DOX cells (51.7% 6 3.5 viable cells). As shown in
Figure 5, the combination of ara-C with Bcl-2-AS for 72 hours
signiﬁcantly enhanced killing of HL-60 sensitive and resistant cells
by Bcl-2-AS.Treatment with NS had no effect on viability, whereas
the combination of ara-C and Bcl-2-AS in HL-60 cells signiﬁcantly
reduced the amount of Bcl-2-AS necessary to reach maximal
cytotoxicity from 12 to 4 µmol/L. In HL-60-DOX cells with higher
baseline levels of Bcl-2, Bcl-2-AS alone was not able to eliminate
all viable cells, regardless of the dose. In contrast, the combination
of ara-C and Bcl-2-AS exhibited maximal cytotoxicity at 16 µmol/L.
NS did not enhance cytotoxicity of ara-C, even at high levels.
Bcl-2-AS reduces viability of AML blasts in vitro. Effect of
Bcl-2-AS on the cell growth of leukemic blasts in vitro was
investigated in samples from patients withAML by cell count with
trypan blue-dye exclusion. The patients’ characteristics are shown
in Table 1. In the majority of the patients, a decrease in cell
numbers was documented after 5 days of culture in the presence of
8 µmol/L Bcl-2-AS, compared with the number of cells in culture
after 5 days without oligodeoxynucleotides (2.3 6 0.3 3 105
cells/mL vs 3.6 6 0.4 3 105 cells/mL; P , .001). In contrast,
very little toxicity was observed in cultures with NS
(3.1 6 0.3 3 105 cells/mL).
Bcl-2-AS induces apoptosis in primary AML samples. We
examined the effect of Bcl-2-AS on the induction of apoptosis in
leukemic cells using ﬂow cytometry to determine the apoptotic
‘‘sub G1’’cells by staining with acridine orange. Examples of ﬂow
cytometric results are represented in Figure 6.
A B
Figure 3. Expression of Bcl-2 in HL-60 cells. (A) Bcl-2 expression of HL-60 cells
after treatment with 8 µmol/L of Bcl-2-AS for 5 days. Although the level of Bax
expression is unchanged, Bcl-2 is decreased in cells treated with Bcl-2-AS. (B)
Expression of Bcl-2 and Bcl-XL in HL-60-DOX cells by Western blot analysis. Ratios
to actin shown were obtained by densitometry.
Figure 4. Effect of Bcl-2-AS on Bcl-2 expression of HL-60 and HL-60-DOX cells.
Bcl-2 protein expression of HL-60 (A) and HL-60-DOX (B) was analyzed by ﬂow
cytometry as described above after gating on live cells. The relative channel number
was measured from the upper limit of the negative control. The relative channel
number of a series of calibrated FITC microbeads having levels of ﬂuorescence
intensity ranging from 8.857 3 103 to 206.086 3 103 antibody-binding capacity
(ABC) of equivalent soluble ﬂuorochrome per bead was calculated (FCSC Quantum;
Becton Dickinson) and a standard curve constructed. The relative channel number
and the antibody-binding capacity per cell for the test samples were calculated using
this standard curve. Results demonstrate lower Bcl-2 expression of cells treated with
8 µmol/Lof Bcl-2-AS for 5 days.
Figure 5. Bcl-2-AS increased sensitivity to ara-C in both HL-60 and in HL-60-
DOX cells. Combined effect of Bcl-2-AS and ara-C on the growth of leukemic cell
lines was tested using the MTS assay after 72 hours of treatment. Note that higher
concentrations of Bcl-2-AS were required in HL-DOX cells because they expressed
higher levels of Bcl-2.
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ment with NS compared with spontaneous apoptosis in control
cultures (18.6% 6 4.5% vs 15.1% 6 4.3%; P 5 .1). Treatment of
AML blasts with Bcl-2-AS caused a signiﬁcant induction of
apoptosis in a dose-dependent fashion in 11 of 19 patient samples
(57.9%). Overall, 27.3% 6 6.3% of apoptotic cells were detected
at a concentration of 4 µmol/L Bcl-2-AS, and 37.0% 6 8.6% at 8
µmol/L (P , .05). Two groups of samples could readily be
separated: those that had an apoptotic response to Bcl-2-AS (group
I), and those that did not (group II). In samples that responded
(group I, n 5 11), we detected 37.5% 6 8.2% apoptotic cells in
cultures with 8 µmol/L Bcl-2-AS, compared with the percentage of
apoptotic cells in cultures with 8 µmol/L NS (17.3% 6 5.2%) and
control cultures (17.5% 6 5.2%; P , .005) (Figure 7). In 8 of 19
patient samples (42.1%, group II), an equal percentage of apoptotic
cells was observed in cultures treated with Bcl-2-AS
(25.1% 6 7.4%) and NS (23.2 6 6.7; P 5 .2). In group I samples,
cell numbers in cultures treated with Bcl-2-AS (1.8 6 0.3 3 105)
were also lower than in group II samples (2.7 6 0.4).
We then analyzed the relationship between the amount of
Bcl-2-AS used and the ability to induce apoptosis. In 8 samples
from group I, increasing concentrations of Bcl-2-AS resulted in a
dose-dependent increase in the percentage of apoptotic cells,
reaching 65.3% 6 9.1% at 10 µmol/L Bcl-2-AS (P , .01) (Figure
Table 1. Clinical data for patients with acute myeloid leukemia
N
Age
(y) Sex Cytogenetic abnormality
FAB
category
Source
%o f
blasts Response
1 34 M Relapsed M0 Diploid PB 93% Failure
2 81 M M0 Diploid BM 80.4% CR
3 46 F M1 relapse Diploid PB 95% CR
4 73 M Sec M4Eo (RA) Inv16 BM 46% Death during induction
5 62 M M0 Diploid BM 95% CR
6 70 F Sec M2 (MDS) 25, 27, del7 BM 81.3% Resistant
7 66 M SecAML (CT for leiomyosarcoma) t(9;11) BM 89% CR
8 72 M Sec M2 (CT for prostate Ca) Diploid BM 84% CR
9 72 M MDS-AML M4 Del 5q BM 65% No follow-up
10 73 M Sec M1 (prostate Ca) Diploid PB 59% Primary resistant
11 75 M M4Eo Inv16 BM 40.8% Failure
12 49 F M1 relapse Diploid BM 90.4% Primary resistant
13 49 F Sec M4 (breast Ca) Diploid BM 56% CR
14 22 F M1 Iso17Q,10Q BM 90% CR
15 45 F M4 t(1;16), t(2;3) BM 64% CR
16 32 M 2d relapse M0 Diploid BM 70.4% CR
17 75 M M4Eos 18, inv16 BM 72% CR
18 59 F M2 Diploid BM 86% Failure
19 82 M Sec M1 (MDS) Diploid BM 81% Refused treatment
FAB, French-American-British classiﬁcation; PB, peripheral blood; BM, bone marrow; CR, complete remission; sec, secondary; RA, refractory anemia; inv16, inversion 16;
MDS, myelodysplastic syndrome;AML, acute myeloid leukemia; CT, chemotherapy; Ca, carcinoma; del, deletion; iso17q, isochromosome 17q.
Figure 6. Flow cytometric determination of apopto-
sis induced by Bcl-2-AS in primary AML cells. AML
blasts were incubated in the presence of 8 µmol/L of
Bcl-2-AS for 5 days as described in ‘‘Materials and
methods.’’ Detection of apoptotic cells (cells in the
subG1 region) was based on DNAfragmentation.
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even at 12 µmol/LBcl-2-AS.
Bcl-2-AS increases proliferation of AML blasts. To investi-
gate the potential effect of Bcl-2-AS on proliferation of leukemic
cells, we performed cell cycle analysis of AML blasts treated with
different concentrations of Bcl-2-AS. In 5 of 6 cases, we observed
an increase in the percentage of S-phase cells after treatment with
low concentrations of Bcl-2-AS (4 samples: 4 µmol/L; 1 sample: 2
µmol/L) (Table 2). In 5 of 6 samples, increases in cells in S-phase
were observed. For the entire group, the increase was signiﬁcant
(P 5 .04). No signiﬁcant change in the percentage of cells in G2M
was observed. At higher concentrations of Bcl-2-AS that induced
apoptotic changes in leukemic cells, no cell cycle effect was
observed (data not shown). Representative examples of DNA
histograms are shown in Figure 9.
Bcl-2-AS inhibits colony-formation ability of AML blasts. To
determine the effect of Bcl-2-AS on myeloid progenitor cells, we
studied the colony-forming ability of leukemic blasts from 5
patients with newly diagnosedAMLin which the blast count was in
excess of 80% (before density gradient separation). Results demon-
strated that in 4 of the 5 patient samples, treatment with Bcl-2-AS
signiﬁcantly (P 5 .01) inhibited the growth of AML colony-
forming cells at 8 and 12 µmol/L (Figure 10). NS at the highest
concentration (12 µmol/L) and empty liposomes had no statistically
signiﬁcant effect on the colony-forming capacity of AML
progenitors.
We observed signiﬁcant toxicity of empty liposomes and of 12
µmol/L NS in the CFU assays for normal CD341 cells, with the
highest concentration of Bcl-2-AS being slightly more inhibitory
than NS (control 357 6 73, empty liposomes 200 6 88, NS
138 6 58, Bcl-2-AS 104 6 74 CFU-GM colonies, P . .5). Like-
wise, at 6 µmol/L, no signiﬁcant difference was found in the
number of CFU-GMs after treatment with Bcl-2-AS, compared
with NS (NS 227 6 73, Bcl-2-AS 257 6 81 CFU-GM colonies).
Reduction of Bcl-2 expression in acute myeloid leukemia
progenitor cells by Bcl-2-AS
CD341 AML blasts from 14 patients were studied using ﬂow
cytometry to determine Bcl-2 levels before and after exposure to
Bcl-2-AS. Baseline Bcl-2 content showed a signiﬁcant degree of
variability ranging from 10.7 3 103 to 155.1 3 103 ABC per cell
(mean, 43.4 6 8.3 3 103 ABC per cell). In all except 1 sample, a
decrease in Bcl-2 levels was observed after 5 days of incubation
with 8 µmol/L Bcl-2-AS, compared with control (untreated) and
NS-treated cultures. In 4 of 18 primary AML samples, increased
Bcl-2 expression was noted in control cultures, compared with
baseline (preculture) levels. The calculated mean antibody-binding
capacity was signiﬁcantly lower in CD341 blasts treated with
Bcl-2-AS (34.9 6 7.8 3 103 ABC per cell) compared with control
cells (47.1 6 8.4 3 103 ABC per cell) or those treated with NS
(53.5 6 8.6 3 103 ABC per cell) (P , .01) (Figure 11). The mean
decrease in Bcl-2 levels in CD341 blasts treated with Bcl-2-AS was
not different in samples in which a response in vitro was observed
(11.4 6 2.4 3 103 ABC per cell) from that in group II samples
without response (16.3 6 3.1 3 103 ABC per cell; P 5 .1). How-
ever, the baseline Bcl-2 levels in leukemic progenitors of group II
samples were signiﬁcantly higher than those in group I cells:
65.3 6 15.4 3 103 versus 25.9 6 2.9 3 103 ABC per CD34 cell
(P 5 .01). Regression analysis demonstrated an inverse correlation
between baseline Bcl-2 protein levels and viability after treatment
with Bcl-2-AS (R2 5 0.4, P 5 .01).
Inhibition of Bcl-2 expression increases the cytotoxicity of
ara-C in sensitiveAMLcells. We next examined the sensitivity of
AML blasts treated with Bcl-2-AS to the cytotoxic drug ara-C.
AML blasts from 13 patients were simultaneously treated with 1
µmol/Lara-C and 8 µmol/LBcl-2-AS for 72 hours and analyzed for
apoptosis by DNA content (Table 3). Ara-C in the presence of
Bcl-2-AS signiﬁcantly increased apoptosis in all samples that were
responsive to treatment with Bcl-2-AS alone (P , .05). No signiﬁ-
cant difference was seen in blasts cultured with ara-C alone or
cultured with ara-C and NS (P . .4). Interestingly, in these
samples, Bcl-2-AS induced the same degree of apoptosis as ara-C
Figure 8. Bcl-2-AS induced dose-dependent apoptosis in primary AML in vitro.
Results are represented as mean 6 SE of mean of the percentage of apoptotic cells
in responsive (group I) and nonresponsive (group II) AML blasts after treatment with
indicated concentrations of Bcl-2-AS.
Table 2. Effect of Bcl-2-AS on cell proliferation of primary acute myeloid
leukemia in vitro
S-phase cells (%)
Bcl-2-AS NS
AML 1 17.7 11.8
AML 2 18.4 13.2
AML 3 15.4 9.3
AML 4 17.2 13.3
AML 5 3.1 1.7
AML 6 2.4 4.5
P-value 0.04
AML, acute myeloid leukemia; Bcl-2-AS, Bcl-2 antisense oligodeoxynucleotides;
NS, nonsense oligodeozynucleotides.
The percentage of cells in S-phase of the cell cycle was analyzed using the
ModFit program after acridine orange staining. In 5 of 6 samples analyzed, S-phase
increased.
Figure 7. Induction of apoptosis by Bcl-2-AS in primary AML cells. AML cells
were treated with 8 µmol/L of Bcl-2-AS for 5 days as described in ‘‘Materials and
methods.’’ Results are represented as mean 6 SEM of the percentage of apoptotic
cells in responsive (group I) and nonresponsive (group II) AML blasts after treatment
with Bcl-2-AS.
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2-AS nonresponsive blasts, Bcl-2-AS sensitized leukemic cells to
ara-C treatment in only 1 of 6 samples. Finally, the level of Bcl-2
expression did not change in responsive or nonresponsive blasts
after the addition of ara-C (Table 3).
Bcl-2-AS induces apoptosis in primaryAMLin the presence of
other antiapoptotic genes. As shown in Table 4, several other
proapoptotic and antiapoptotic genes were found to be expressed in
the AML samples tested. Besides Bcl-2, the antiapoptotic genes
Bcl-XL, Bag1, A1 and Mcl-1 were expressed as determined by
Western blot analysis, at various levels, in 5 of 6 samples studied
(Figure 12). By RT-PCR, all AML samples (10 of 10) tested
expressed these antiapoptotic proteins (data not shown). This was
also true when the samples sensitive to the induction of apoptosis
by Bcl-2-AS (group I) were analyzed separately: Antiapoptotic
genes were expressed in 6 of 6 samples by RT-PCR and in 3 of 4
samples by Western blot analysis (Table 4).
In vitro response to Bcl-2-AS correlates with response to
chemotherapy in vivo. We then compared the ability to induce
apoptosis in AML cells cultured in vitro with Bcl-2-AS with the
response to induction chemotherapy in patients. All patients
were treated with high-dose ara-C in combination with idarubicin
or topotecan on University of Texas M. D. Anderson Cancer
Center protocols. Complete remissions were achieved in 7 of 9
patients whose blasts responded in vitro to Bcl-2-AS, but only in 2
of 7 patients whose blasts did not respond to Bcl-2-AS (P 5 .04).
No correlation with percentage of blast cells or cytogenetics
was found.
Discussion
The emergence of resistance to chemotherapeutic agents remains a
major problem in the treatment of AML, despite the fact that
patients usually have a good initial response to chemotherapy. The
Bcl-2 protein can block apoptosis by most chemotherapeutic
agents,6,51 and has been found to be expressed at high levels in
AMLblasts capable of autonomous growth in vitro.52 Our own data
indicate that virtually all AML samples express Bcl-2.53 This
ubiquitous expression of Bcl-2 in AML cells may be an important
survival factor for those cells. Several studies, including our own,
have identiﬁed Bcl-2 levels as prognostic in AML.10-14,53,54 The
prognostic impact depends on the cytogenetic abnormalities of the
AMLs studied.53 An earlier study by Keith et al29 demonstrated
induction of apoptosis by Bcl-2-AS in vitro in fresh AML samples
as well as increased chemosensitivity to ara-C. However, they
reported decreased levels of Bcl-2 expression after Bcl-2-AS in
fewer than 50% of the samples studied. This was thought to
be related to the poor bioavailability of the phosphorothioate
Figure 9. DNAhistograms of Bcl-2-AS- or NS-treated leukemic cells from 3AML
samples. Cellular DNA content was measured by acridine orange as described in
‘‘Materials and methods.’’ The curve ﬁtting software (ModFit) allowed the determina-
tion of the percentage of cells in different phases of cell cycle. In all samples shown,
S-phase increased in Bcl-2-AS–treated samples, compared with NS controls.
Figure 10. Inﬂuence of Bcl-2-AS on myeloid leukemia clonogenic progenitor
growth of primary AML cells. Data represent average results from 5 different
samples. Results are expressed as mean 6 SEM of the number of colonies in the
presence of increasing concentrations of Bcl-2-AS (4, 6, 8, and 12 µmol/L), compared
with control cells or cells treated with nonsense (12 µmol/L) or empty liposomes.
Asterisk (*) indicates signiﬁcance at P , .05. EL, empty liposomes.
Figure 11. Decrease of Bcl-2 expression in AML cells after treatment with
Bcl-2-AS. Bcl-2 expression was determined by quantitative ﬂow cytometry as
described in ‘‘Materials and methods’’ after gating on live cells. Results are
represented as mean 6 SEM of the ABC of sensitive (responsive) and resistant
(nonresponsive) cells at baseline (preculture) and after treatment with Bcl-2-AS, NS,
and in control cultures without ODNs. In both types of cells, 8 µmol/L of Bcl-2-AS
caused a signiﬁcant (P , .05) decrease in Bcl-2 expression.
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apoptosis in AML by quantitating cellular Bcl-2 levels before and
after Bcl-2-AS and by also determining other antiapoptotic pro-
teins. We also investigated mechanisms of resistance of leukemic
cells to Bcl-2-AS.
As a model, we used 2 myeloid leukemic cell lines with
different levels of Bcl-2 expression. In both cell lines tested,
Bcl-2-AS was able to decrease cell viability and to induce
apoptosis after a decrease in the level of Bcl-2 expression.
HL-60-DOX cells, which express high levels of Bcl-2, required
higher concentrations of Bcl-2-AS to achieve toxicity equivalent to
that achieved in HL-60 cells. No substantial toxicity was observed
in cells treated with NS or empty liposomes. Remarkably, down-
regulation of Bcl-2 resulted in decreased cell survival despite
overexpression of antiapoptotic Bcl-XL (and MDR-1) in this cell
line.37 Bcl-2-AS also potentiated ara-C-induced cytotoxicity in
both cell lines, resulting in complete cell kill in cells resistant to
ara-C alone.
In primary AML samples, liposomal Bcl-2-AS signiﬁcantly
reduced Bcl-2 expression in all except 1 sample studied at a
concentration of 8 µmol/L, which was found to be effective in the
resistant cell line HL-60-DOX. Viability decreased and apoptosis
was induced in 11 of 19 patient samples (57.9%). Bcl-2-AS also
inhibited the colony-forming ability ofAMLblasts in 4 of 5 patient
samples tested when used at 8 or 12 µmol/L. None or very little
nonspeciﬁc toxicity was observed after in vitro treatment with
control (NS) or with empty liposomes. In the resistant samples,
Bcl-2-AS led to an identical decrease in the level of Bcl-2
expression as that found in nonresistant samples (11.4 6 2.4 3 103
ABC per cell and 16.3 6 3.1 3 103 ABC per cell, respectively)
(P 5 .1), but had no effect on cell viability. In these samples, the
baseline levels of Bcl-2 were strikingly higher than in the sensitive
samples. Regression analysis revealed an inverse correlation
between baseline levels of Bcl-2 protein expression and viability of
primaryAMLcells after treatment with Bcl-2-AS. Only in samples
with low levels of Bcl-2 expression was Bcl-2-AS able to sensitize
AML blasts to ara-C. These results suggest that there is a critical
threshold for Bcl-2 above which it supports the spontaneous
survival of leukemic cells, prevents apoptosis, and protects from
ara-C toxicity. The ﬁnding that induction chemotherapy resulted in
remissions in 7 of 9 patients whose cells were susceptible to
Bcl-2-AS apoptosis but failed in 5 of 7 patients in the Bcl-2-AS–
resistant group II, suggests the possibility that similar mechanisms
might be operational in vitro and in vivo. In Bcl-2-AS–resistant
leukemias, Bcl-2 would act as a survival factor for disease and
prevent achievement of complete remission. In patients with lower
baseline levels of Bcl-2, down-regulation by Bcl-2-AS–induced
apoptosis. These patients would most likely beneﬁt from the
clinical use of Bcl-2-AS. Interestingly, in 2 patients who failed to
Figure 12. Expression of Bcl-2 family proteins inAML by Western blot analysis.
For details, see ‘‘Results.’’
Table 4. Expression of Bcl-2 family members in primary acute myeloid
leukemia treated with Bcl-2-AS by Western blot analysis
Bcl-2-AS sensitive
(group I)
(N 5 4)
Bcl-2-AS resistant
(group II)
(N 5 2)
Anti
Bcl-XL 3/4 2/2
Bag-1 4/4 2/2
A1 4/4 2/2
Mcl-1 1/1 1/1
Pro
Bax 4/4 2/2
Bad 4/4 1/2
Bak 3/4 2/2
Bcl-2-AS, Bcl-2 antisense oligodeoxynucleotides.
Expression of anti- (Bcl-XL, Bag-1,A1, Mcl-1) and pro- (Bad, Bak, Bax) apoptotic
members of Bcl-2 protein family was analyzed by Western blot analysis as described
in ‘‘Materials and methods.’’ The results are presented as the number of positive
samples.
Table 3. Bcl-2-AS increases apoptosis induced by ara-C
Samples
Subdiploid apoptotic cells (%) Bcl-2 expression (3103ABC per cell)
Control NS Bcl-2-AS Control NS Bcl-2-AS
Responsive blasts (N 5 7)
No ara-C 18.5 6 5.6 26.9 6 6.6 43.8 6 8.1 23.7 6 7.8 25.7 6 5.4 16.7 6 5.5
Ara-C 42.3 6 5.8 42.6 6 5.8 61.7 6 7.0 30.4 6 7.1 29.2 6 8.1 13.5 6 3.0
Nonresponsive blasts (N 5 6)
No ara-C 20.5 6 5.7 18.9 6 5.4 20.5 6 5.7 49.2 6 9.9 53.0 6 6.2 35.3 6 6.7
Ara-C 46.4 6 11.2 42.5 6 11.0 42.3 6 11.6 42.8 6 5.8 44.6 6 6.3 36.3 6 4.5
Bcl-2-AS, Bcl-2 antisense oligodeoxynucleotides;ABC, antibody-binding capacity; NS, nonsense oligodeoxynucleotides.
The percentage of apoptotic cells was determined using ﬂow cytometry of acridine orange staining as described in ‘‘Materials and methods.’’The combination of Bcl-2-AS
with 1 µmol/L ara-C signiﬁcantly (P , .05) enhanced ara-C induced apoptosis in responsive blast samples but not in nonresponsive blast samples after 72 hours of treatment.
The level of Bcl-2 expression in AML cells treated with Bcl-2-AS or NS did not change signiﬁcantly when ara-C was added. All measurements of the Bcl-2 expression were
analyzed after appropriate gating on live CD341AMLcells.
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vitro, therefore overcoming other drug-resistance mechanisms such
as overexpression of other antiapoptotic genes. Many other resis-
tance factors are known in AML and in AML cell lines. HL-60-
DOX cells not only express high levels of Bcl-2, but also Bcl-XL.37
Using complementary DNA(cDNA) technology, we have recently
identiﬁed 29 genes that are overexpressed in HL-60-DOX, com-
pared with HL-60 cells.55 Many of these are associated with drug
resistance.Analysis of the primary samples tested here by RT-PCR
and Western blot demonstrated expression of several antiapoptotic
genes, including Bcl-XL, A1, Bag-1, and Mcl-1. We have also
recently shown that antiapoptotic IAP family members are ex-
pressed in primaryAMLsamples including IAP1, IAP2, NAIP, and
in particular XIAP, which was expressed at high levels in 100% of
samples examined.56The ability of Bcl-2-AS to induce apoptosis in
these cells is remarkable and points to the crucial role of this
protein for their survival. Interestingly, after Bcl-2-AS, increased
expression of Bcl-XL was observed in HL-DOX cells. In cases
resistant to the effect of Bcl-2-AS alone, targeting multiple
mechanisms of resistance might be necessary to induce cell death.
Antiapoptotic protein Bcl-XL that is highly expressed in AML57 is
associated with autonomous growth in vitro and with P-
glycoprotein expression.34 The ratio of Bcl-XS to Bcl-XL is
different in good- and poor-prognosis subsets of acute myeloid
leukemia.35 Thus, down-regulation of both Bcl-2 and Bcl-XL could
be beneﬁcial for these patients. In mdr-1–expressing AML, a
strategy of combining Bcl-2-AS with mdr-1 blockers might
be effective.
Our data indicate that down-regulation of Bcl-2 induces apopto-
sis in leukemia cell lines and in primary AML samples with low
baseline levels of Bcl-2 expression. Recent evidence suggests that
low levels of Bcl-2 expression in AML patients with poor-
prognosis cytogenetics is associated with decreased survival.53
This appears to violate the dogma that high levels of Bcl-2 protect
cells from chemotherapy-induced apoptosis. Likewise, low levels
of Bcl-2 were shown to be a poor prognostic factor in patients with
breast, lung, and colon cancer.58-61 These ﬁndings are presumably
associated with the evolving concept of an antiproliferative effect
of high levels of Bcl-2 expression. In this context, high Bcl-2
expression would delay relapse or regrowth of tumor cells by virtue
of their lower proliferative activity. Although proliferating cells
with lower Bcl-2 expression may be more sensitive to chemother-
apy or radiotherapy, those with high Bcl-2 expression would
regrow at a slower rate. The down-regulation of Bcl-2 could
counteract the antiproliferative function of Bcl-2, increase cell
proliferation, and therefore facilitate killing by cell-cycle–
dependent drugs. In a clinical trial with all-trans retinoic acid in
acute promyelocytic leukemia, we noted that the proliferation of
leukemic cells was indeed temporarily increased.62 This effect was
presumably the result of down-regulation and/or phosphorylation
of Bcl-2 by all-trans retinoic acid. In our experiments, low doses of
Bcl-2-AS recruited leukemic cells into the S phase of the cell cycle
in 5 of 6 AML samples tested. Perhaps down-regulation of Bcl-2
ﬁrst blocks its antiproliferative effect, followed by induction of cell
death. In favor of this hypothesis was the ﬁnding that in 3 of 6AML
samples in which Bcl-2-AS increased the number of S-phase cells,
apoptosis was not induced. At higher concentrations of Bcl-2-AS,
induction of cell death with concomitant decrease of the prolifera-
tive fraction was observed. Therefore, Bcl-2-AS could sensitize
leukemic cells by both enhanced apoptosis and recruitment into the
cell cycle.
In conclusion, results indicate that the administration of Bcl-
2-AS in vivo in patients with AML whose blast cells express low
levels of Bcl-2 could generate targets with differential sensitivity to
chemotherapy. Experiments inAML NOD-SCID model are under-
way to test whether Bcl-2-AS affects SCID-repopulating AML
cells. It is known that the earliest normal hematopoietic progenitors
do not express Bcl-2 but instead express high levels of Bcl-XL.21;22
The ﬁrst human clinical trial of Bcl-2 antisense phosphorothioate
ODN in patients with recurrent non-Hodgkin lymphomas showed
few side effects and clinical responses in some patients.25 Also,
sensitization to chemotherapy previously found to be ineffective
was observed in 6 of 8 patients. Hence, the elucidation of the
molecular mechanisms of action of Bcl-2 may create the basis for
the therapeutic correction of this disease-mediated dysfunction of
cell death control.
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